Suchergebnisse - "Goligher, Ewan C"

PubPharm (10)

1

Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19-Reply

enthalten in: JAMA | 2023

von Goligher, E. | Lawler, P. | Zarychanski, R.

CommentOn: JAMA. 2023 Aug 1;330(5):471-472. - PMID 37526726

2

Continuation of therapeutic dose heparin for critically ill patients with COVID-19

enthalten in: Intensive care medicine | 2023

von Bradbury, C. | Lawler, P. | McVerry, B. | +81

3

Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19

enthalten in: JAMA | 2023

von Goligher, E. | Lawler, P. | Jensen, T. | +120

CommentIn: JAMA. 2023 Apr 4;329(13):1063-1065. - PMID 36942555

4

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

enthalten in: JAMA | 2023

von Writing Committee for the REMAP-CAP Investigators | Higgins, A. | Berry, L. | +164

CommentIn: JAMA. 2023 Jan 3;329(1):25-27. - PMID 36525259

5

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19 : A Randomized Clinical Trial

enthalten in: JAMA | 2022

von REMAP-CAP Writing Committee for the REMAP-CAP Investigators | Bradbury, C. | Lawler, P. | +171

CommentIn: JAMA. 2022 Apr 5;327(13):1234-1235. - PMID 35315488

6

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19 : A Randomized Clinical Trial

enthalten in: JAMA | 2022

von Berger, J. | Kornblith, L. | Gong, M. | +132

CommentIn: JAMA. 2022 Jan 18;327(3):223-224. - PMID 35040901

7

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

enthalten in: The New England journal of medicine | 2021

von REMAP-CAP Investigators | ACTIV-4a Investigators | ATTACC Investigators | +98

CommentIn: Thromb Res. 2021 Dec;208:35-38. - PMID 34688100

8

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

enthalten in: The New England journal of medicine | 2021

von ATTACC Investigators | ACTIV-4a Investigators | REMAP-CAP Investigators | +98

CommentIn: N Engl J Med. 2021 Nov 18;385(21):2013. - PMID 34788515

9

Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19

enthalten in: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne | 2020

von Godoy, L. | Goligher, E. | Lawler, P. | +2

10

Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) : Study design and methodology for an international, adaptive Bayesian randomized controlled trial

enthalten in: Clinical trials (London, England) | 2020

von Houston, B. | Lawler, P. | Goligher, E. | +24

1
[1]